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Background: Tuberculous meningitis (TBM) is the most lethal and 
disabling form of tuberculosis. Delayed diagnosis and treatment, 
which is a risk factor for poor outcome, is caused in part by lack of 
availability of diagnostic tests that are both rapid and accurate. 
Several attempts have been made to develop clinical scoring systems 
to fill this gap, but none have performed sufficiently well to be broadly 
implemented. We aim to identify and validate a set of clinical 
predictors that accurately classify TBM using individual patient data 
(IPD) from published studies. 
Methods: We will perform a systematic review and obtain IPD from 
studies published from the year 1990 which undertook diagnostic 
testing for TBM in adolescents or adults using at least one of, 
microscopy for acid-fast bacilli, commercial nucleic acid amplification 
test for Mycobacterium tuberculosis or mycobacterial culture of 
cerebrospinal fluid.  Clinical data that have previously been shown to 
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be associated with TBM, and can inform the final diagnosis, will be 
requested. The data-set will be divided into training and 
test/validation data-sets for model building. A predictive logistic 
model will be built using a training set with patients with definite TBM 
and no TBM. Should it be warranted, factor analysis may be employed, 
depending on evidence for multicollinearity or the case for including 
latent variables in the model. 
Discussion: We will systematically identify and extract key clinical 
parameters associated with TBM from published studies and use a 
‘big data’ approach to develop and validate a clinical prediction model 
with enhanced generalisability. The final model will be made available 
through a smartphone application. Further work will be external 
validation of the model and test of efficacy in a randomised controlled 
trial.
Keywords 
Tuberculous meningitis, multivariable prediction rule, machine 
learning, diagnostics
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Introduction
Tuberculosis remains a major global health problem, with the 
most lethal and disabling form being tuberculous meningitis 
(TBM), of which there are more than 100,000 new cases each 
year1. Mortality is high, particularly in children and patients who 
are co-infected with HIV-12. The diagnosis is often delayed by 
the insensitive and lengthy culture technique required for disease 
confirmation, with delayed diagnosis and treatment being 
important risk factors for poor outcome1. Recently introduced 
nucleic acid amplification tests (NAATs) allow more rapid 
detection of TBM. Pooled specificity of 98.0% and 90% for 
Xpert MTB/RIF and Xpert MTB/RIF Ultra respectively, sug-
gest that they are effective rule-in tests with the potential to speed 
up diagnosis and reduce unnecessary treatments for alterna-
tive conditions in some patients. However, the pooled sensitivity 
is 71.1% and 90% respectively, which is even lower for 
patients with HIV (58% to 81%)3. Given the extremely high 
mortality if treatment is withheld from patients with TBM, 
these values are unlikely to be sufficient evidence to withhold 
treatment when negative in most patients. Improved strategies 
to rapidly and accurately diagnose TBM are urgently needed1.
A major stumbling block in TBM research had been the absence 
of a single reference standard test or standardised diagnostic 
criteria. In 2010, a committee of 41 international experts in the 
field developed consensus case definitions for TBM for use in 
clinical research4. These case definitions have helped to stand-
ardise research but are not appropriate for use in routine clinical 
care as they depend on variables such as cerebrospinal fluid 
(CSF) culture results, which can take up to 6 weeks to become 
positive and may include brain imaging, which is not available in 
many resource constrained settings.
Another approach to improving rapid diagnosis in TBM, 
particularly in resource-limited settings where the majority of 
cases occur, is to develop and validate multivariable prediction 
models. At least 10 models have been published for the diagno-
sis of TBM, but a major limitation is that their performance is 
variable in different populations and settings1. A major reason 
for heterogeneous model performance across different settings 
and populations is case mix variation, which refers to the 
distribution of important predictor variables such as HIV status 
and age, and the prevalence of TBM. Case mix variation across 
different settings or populations can lead to genuine differ-
ences in the performance of a prediction model, even when the 
true predictor effects are consistent (that is, when the effect of a 
particular predictor on outcome risk is the same regardless of 
the study population)5. 
Recent studies have shown how big datasets can be used to 
examine heterogeneity and improve the predictive performance 
of a model across different populations, settings, and subgroups6–8. 
Individual patient data meta-analysis is preferred to aggregate 
data meta-analysis, as risk scores can be generated and validated, 
and multiple individual level factors can be examined in 
combination9. 
Objectives
1.    Conduct a systematic review to identify studies that applied 
systematic diagnostic strategies for TBM in adolescents 
and adults presenting with meningitis
2.    Establish an international collaboration among TBM 
research groups who are willing to provide individual 
patient data (IPD)
3.    Use IPD to develop a clinical prediction model that 
estimates the probability of TBM in adolescent and 
adults, based on clinical and laboratory data that is 
routinely available within 48 hours of initial evaluation
Secondary objectives include an assessment of the number 
and quality of studies addressing the diagnosis of TBM, as well 
as an analysis of demographic and clinical characteristics of 
cases and non-cases of TBM.
Protocol
A systematic review and IPD meta-analysis will be performed 
according to Preferred Reporting Items for Systematic review 
and Meta-Analysis of IPD (PRISMA-IPD) guidelines10.
Identification of studies
Potentially eligible studies will be identified by an extensive 
search of electronic databases, manual search of reference lists and 
by contacting researchers with interest and expertise in meningitis 
who may have access to unpublished studies.
We have designed a broad search strategy to maximise 
sensitivity. We will combine medical subject heading (MeSH) 
and free text terms to identify relevant studies, see Table 1. We 
will search Medline (accessed via PubMed), Africa-Wide Infor-
mation and CINAHL (both accessed via EBSCO Host). We will 
not limit our searches by geographical location. The search 
will be restricted to studies published after 01 January 1990 and 
in English. The detailed search strategies will be presented in an 
online supplementary appendix. Reference lists of the selected 




•    Randomized controlled trials, cross-sectional studies, and 
observational cohort studies
•    Participants presenting to care with clinical meningitis
•    Use of at least 1 of microscopy for acid-fast bacilli, 
commercial nucleic acid amplification test (NAAT) for 
Mycobacterium tuberculosis or mycobacterial culture of 
CSF to diagnose TBM
•    Study includes a minimum of 10 participants aged ≥ 13 
years
          Amendments from Version 2
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Exclusion criteria
•    Case-control studies and case reports/series of patients 
with confirmed TBM
•    Participants taking anti-TB drugs at the time of their 
evaluation
•   Non-English articles
•   Studies published before 1990
•   Full text unable to be located
•   Studies not in humans
Screening and study selection
Duplicate studies will be removed. Study selection will follow 
the process described in the Cochrane Handbook of Systematic 
Reviews and PRISMA-IPD statements10. Two investigators will 
independently screen titles and abstracts to remove irrelevant 
studies. Full text review will be performed on the remaining 
studies to determine eligibility. Any disagreements will be 
resolved by consensus or in consultation with a third reviewer.
Data extraction
Data will be extracted on a proforma, independently by two 
review authors on study level variables: study setting and dates; 
contact details; inclusion criteria and exclusion criteria, and 
number of patients. Corresponding authors of studies identified 
as eligible after full text review will be contacted with a request 
to provide anonymised individual patient data. IPD for vari-
ables that have previously been shown to be predictive of 
TBM1 and competing diagnoses will be requested, Table 2. 
Investigators will be requested to share their anonymised data 
after obtaining a signed agreement.
Data management
Investigators will be asked to share anonymised individual 
patient data, preferably electronically using encrypted files and 
other secure data transfer technologies using standardised data 
collection forms. Only study collaborators will have access to 
the combined IPD data available in Box. Box Secure Storage is 
a cloud storage and collaboration service configured to meet 
the security standards for HIPAA data. Data will remain stored 
in Box for the duration of the study and will not be used or 
sold for any commercial purpose.
Authorship
Authors providing IPD will be asked to nominate co-authors 
to expand the expertise of the review group, including review of 
preliminary findings and manuscript authorship. The number of 
co-authors will depend on the amount of data supplied, 1 author 
for <100 patients, 2 authors for >100 and <250 patients, and 3 
authors for >250 patients.
Quality assessment
Quality assessment in terms of risk of bias and applicability for 
each included study will be performed according the QUADAS-2 
tool for diagnostic accuracy studies11. This tool comprises 
4 domains: patient selection, index test, reference standard, and 
flow and timing. Each domain is assessed in terms of risk of 
bias, and the first 3 domains are also assessed in terms of 
Table 1. Proposed search terms.
Search Query
#1 Search tuberculosis meningitis Field: Title/Abstract
#2 Search “tuberculosis, meningeal”[MeSH ]
#3 Search cerebral tuberculosis Field: Title/Abstract
#4 Search “brain tuberculosis” Field: Title/Abstract
#5 Search TBM Field: Title/Abstract
#6 Search ((((tuberculosis meningitis) OR “tuberculosis, meningeal”[MeSH Terms]) OR 
“cerebral tuberculosis“) OR “brain tuberculosis”) OR TBM
#7 Search “Diagnosis”[Majr]
#8 Search diagnosis or diagnostic Field: Title/Abstract
#9 Search “clinical scores” or “clinical scoring” Field: Title/Abstract
#10 Search “Research Design”[Mesh]
#11 Search predictor* or predictive Filters: Field: Title/Abstract
#12 Search “clinical predict*” Field: Title/Abstract
#13 Search “clinical feature*” Field: Title/Abstract
#14 Search (((#13 OR ((#12) OR ((#11) OR ((#10) OR ((#9) OR #8 OR #7 Filters: Humans
#15 Search #14 AND #6 Filters: Humans
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concerns regarding applicability. Signalling questions are 
included to help judge risk of bias.
Data synthesis
1.  Descriptive analysis of available parameters, data 
completeness check, and IPD meta-analysis.
The contributing datasets will be reviewed for sample size, 
available variables and data completeness, to inform the selec-
tion of a modelling approach. A descriptive analysis will be 
undertaken to understand similarities and differences between 
the contributing datasets. Participant characteristics and clini-
cal features (Table 1) will be summarized for each contributing 
dataset and compared across datasets using chi-square, t-tests, or 
non-parametric methods as warranted.
2.  Selection of Candidate Predictors
The objective of this step will be to reduce the number of 
variables that go into the development of the TBM prediction 
model. Prior studies have indicated several predictive variables 
such as
•  Symptom duration prior to presentation at the hospital 
(days)
•  CSF leukocytes
•  CSF neutrophil (%)
•  CSF glucose
•  CSF protein
We aim to include these variables in the predictive model as 
“primary predictors” in an effort to retain the variables that are 
the most predictive of TBM diagnosis as well as easily acquired 
in low resource settings. Primary predictors will be assessed 
for missingness, imputed if missing (see Step 3 for more 
detail), and will be used in predictive model development. 




•  Blood glucose
•  Blood leukocytes
•  Country
•  HIV status
We aim to include the above secondary predictors in an effort 
to explore their predictive value of diagnosing TBM. The 
secondary predictors have been selected based on prior pub-
lished diagnostic algorithms. They will be assessed for miss-
ingness and imputed if missing (see Step 3 for more detail) 





•   Age* 
•   Sex* 
•   Presence of extrapyramidal movements* 
•   Presence of neck stiffness* 
•   Duration of symptoms* 
•   Focal neurological deficit (including cranial nerve palsy)* 
•   Temperature* 
•   Glasgow Coma Scale* 
•   AVPU score*
•   HIV sero-status* 
•   Total leukocytes* 
•   CD4 count* 
•   Glucose*
•   Appearance* 
•   Total leukocytes* 
•   Total neutrophils* 
•   Total lymphocytes* 
•   Protein* 
•   Glucose* 
•   Gram stain* 
•   Adenosine deaminase activity* 
•   Bacterial culture 
•   India ink stain* 
•   Cryptococcal antigen* and culture 
•   Microscopy for acid-fast bacilli 
•   Mycobacterial culture 
•   NAAT for Mycobacterium tuberculosis 
•   NAAT for any virus 
•   Syphilis serology* 







•   Urine LAM* 
•   Microscopy for acid-fast bacilli* 
•   Mycobacterial culture 
•   NAAT for Mycobacterium tuberculosis*
•   Chest X-ray* 
•    Abdominal ultrasound 
scan
•   CT brain 
•   MRI brain
•   Histological results from autopsy
*Factors chosena priori to be used to develop the initial model�
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but may or may not be included in the final algorithm if their 
addition to the algorithm does not result in better predictive 
performance. It is also possible that age, sex, country, and HIV 
status could explain case-mix variation.
We will also consider employing methods such as principal 
component analysis and joint individual variation explained12 
to identify the variables that explain most of the variation in 
TBM diagnosis to retain in the final model(s).
3.  Multiple Imputation for missing data
Multiple imputation for this study will be carried out within 
contributing datasets that have <65% missing data for the pri-
mary and select secondary predictors; blood glucose and blood 
leukocytes. Characteristics of participants with 10–64.99% 
missing data will be summarized and compared to those with 
‘complete’ data (<10% missing data) to explore the nature of 
missingness and identify auxiliary variables that could later 
inform imputation. Comparison characteristics include sex, age, 
survival time (days), outcome, diagnosis, and TBM case sta-
tus (definite, probable, possible, not-TBM). If there is no 
clear pattern of missingness, the data will be assumed miss-
ing at random and imputed. After imputation, the fraction of 
missing information (FMI) statistic will be estimated in the 
modeling step to ensure that the imputation model is well 
specified13. It is not always reasonable to assume predictors 
missing ≥65% of data are missing at random. Therefore, we 
will attempt to determine the underlying mechanism of miss-
ingness and not impute for these predictors if the missing-
ness cannot be accounted for by another variable with complete 
information or if the missing data appear to be missing not at 
random.
Auxiliary variables such as sex and age, which are typically 
predictive of most biological values, will be used to help inform 
imputation. Further auxiliary variables for each missing predic-
tor will be selected based on biologic plausibility. For exam-
ple, missing CSF glucose will be informed by blood glucose. 
After auxiliary variables are identified for each missing primary 
or secondary predictor, missing data will be imputed within 
each contributing dataset (i.e. not informed with data from other 
contributing datasets.
Multiple imputation will be carried out in R using the MICE 
package. Patients with TBM and other types of meningitis are 
typically acutely ill, therefore we are expecting skewed val-
ues for all the biologic metrics and will be utilizing the chained 
equations approach in the MICE package. We will impute 
20 datasets for each missing variable.
4.  Developing a Predictive Model
After that we will build a predictive algorithm via IPD 
meta-analysis using a logistic regression model for the diagno-
sis of TBM7. The first step is to estimate the predictor–outcome 
associations from the available studies in order to assess 
heterogeneity in predictors across studies. Predictors that have 
homogenous predictor-outcome associations will be prioritized 
in model inclusion, but we will not exclude variables that have 
heterogenous predictor-outcome relationships across studies. 
All predictors will be included in a model with a stratified inter-
cept for each study to underscore the baseline predictor-outcome 
value of each of the predictors in the different contributing 
datasets7. We will also develop a model with a stratified inter-
cept for each country (pooling datasets from the same coun-
try) for the purposes of external validation and implementation 
after the model is developed.
All the data collected from the systematic review will be used 
in the development of the clinical prediction tool. The objec-
tive of this step is to develop three different prediction mod-
els. The first model will be developed using logistic regression 
with backward stepwise variable selection (p-value threshold 
of 0.1)14,15. This is the modeling approach used in prior clinical 
prediction tools developed for TBM. The second model will be 
developed using the IPD meta-analysis framework with a strati-
fied intercept for country7. As discussed earlier, this approach is 
appropriate for these data as it encompasses information from 
multiple contributing datasets in the development of the tool. 
The final model will be developed using machine learning 
techniques such as classification and regression trees or random 
forest classifier analysis.
5.  Testing the model for internal validity
The model(s) will be internally validated using the bootstrap 
and internal-external cross validation approaches. Bootstrap 
validation is the process for which observations from within each 
contributing dataset are sampled with replacement to go into 
the development of the model, the model development analy-
ses are repeated, and then this model is internally validated in 
the original datasets16,17. This validation step will give informa-
tion of optimism and overfitting. Internal-external cross valida-
tion approach is a multiple validation approach that accounts for 
multiple datasets by rotating which are used toward model 
development and validation7. Each contributing dataset will be 
excluded from the available set, and the remainder will be used 
to develop the diagnostic model; the excluded study will then 
be used to validate the model externally. This process will be 
repeated with each study being omitted in turn, allowing the 
consistency of the developed model and its performance to be 
examined on multiple occasions.
Performance of the developed model(s) will be assessed using 
calibration and discrimination, metrics for model fit. Calibra-
tion is defined as the agreement between observed outcomes 
and predictions18. We will use the ratio of predicted (expected) 
to observed outcomes, otherwise known as E/O, to assess 
model calibration. Ideally, the ratio should be close to 1, which 
represents a calibrated model7. Calibration is also related to 
goodness-of-fit, which relates to the ability of a model to fit a 
given set of data18. The Hosmer-Lemeshow goodness-of-fit test 
is often used to assess goodness-of-fit with binary outcome data, 
which can be graphically displayed in a calibration plot. Usu-
ally, patients are grouped by decile of predicted probability. A 
better calibrated model will have the average prediction value 
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within each decile falling along a 45 degree line in the plot, 
where the true probability in each decile (y-axis) is equal to 
the average predicted probability for that group (x-axis)18.
Discrimination is defined as the ability to generate predictions 
that discriminate between those with and those without the 
outcome (e.g. TBM vs not-TBM diagnosis)18. We can assess 
discrimination using a receiver operating characteristic (ROC) 
curve, which plots the sensitivity (true positive rate) against 
1 – specificity (false-positive rate) for consecutive cutoffs for 
the probability of an outcome (i.e. TBM diagnosis). For the 
bootstrap approach, ROC curves will be produced as an aver-
age for the models that are bootstrapped, and discrimination will 
be compared using the area under the curve (AUC) c-statistic. 
For the internal-external cross validation approach, discrimina-
tion will be estimated in each study that is excluded from devel-
opment. The AUC can be interpreted as the probability that a 
patient with the outcome is given a higher probability of the 
outcome by the model than a randomly chosen patient with-
out the outcome18. The higher the AUC, represented by the 
curve closer to the upper left-hand corner (higher sensitivity and 
specificity), the better the model is at predicting the outcome, 
in this case TBM diagnosis. Furthermore, ROC curves are often 
used in diagnostic research to quantify the diagnostic value of a 
test over its whole range of possible cutoffs for classifying 
patients as positive vs. negative18. The curves trend to the upper 
left corner when the distributions of predictions are more separate 
between those with and without the outcome.
Optimism or “overfitting” is where the model fits the data so 
well that it is not valid for new subjects, a key threat to internal 
validity that needs to be addressed throughout the internal vali-
dation process. Model performance statistics are generated and 
then optimism-corrected by taking the apparent performance 
and subtracting the optimism. The optimism for a particular 
statistic is calculated by repeating the model development in 
each bootstrap sample, calculating the performance in the boot-
strap sample (where it will be optimistic), and then applying that 
model back to the original dataset (acting as a validation data-
set). After repeating this process 100–200 times, the average 
of the differences between these model performance statistics 
is the estimate of optimism.
As discussed, high optimism is indicative of overfitting, which 
can be corrected via shrinkage. Shrinkage is defined as the regres-
sion of coefficients towards zero as a way to improve model 
performance18. Although we do not anticipate that we will 
need to employ this method to correct for overfitting because 
we will have completed the data reduction step described in 
step 3 above, we will validate the necessity of the shrinkage 
approach when assessing model optimism.
In addition to assessing model calibration and discrimina-
tion, the Brier score will be used to assess overall model perfor-
mance. The Brier score measures the accuracy of probabilistic 
predictions, which is a combination of both calibration and 
discrimination18,19. The Brier score calculates the squared dif-
ferences between actual outcomes and predictions. For a model, 
the Brier score can range from 0% for a perfect model to 
0.25 for a non-informative model. A Brier score will be 
generated from the model developed in the original dataset.
After the internal validation process, we will select model(s) 
that perform well and calculate the overall sensitivity, specific-
ity, positive predictive value, and negative predictive to assess 
the accuracy of the model(s) in predicting TBM. Due to the 
high mortality among unstable TBM patients a 10% predic-
tive probability will be used as a threshold of a positive case 
status20. Any predictive probability equal to or above 10% will 
be sufficient to treat a patient for tuberculosis since the outcome 
of not treating TBM is almost always death20.
6.  Sensitivity analysis
We will perform the following sensitivity analyses to explore 
the contributions of risk of bias on the final model(s):
•  Exclude studies that investigated all patients for TBM 
regardless of other CSF findings (co-infection). This 
is important for discerning which clinical characteris-
tics are predictive of TBM or other meningitis-causing 
diseases.
•  Develop the prediction model(s) with different TBM-
case status groupings. Confirmed TBM and non-TBM 
cases will remain as such in model development with 
probable and possible cases shifting to either cat-
egory. The model will be developed with the following 
case status groupings:
◦     Confirmed TBM vs. probable, possible, and 
non-TBM
◦     Confirmed and probable TBM vs. possible and 
non-TBM
◦     Confirmed, probable, and possible TBM vs. 
non-TBM
  We will compare the observed heterogeneity, 
clustering, predictor selection, and model performance 
between the models developed with the above case 
groupings. This is important for two reasons. First, 
shifting the threshold of inclusion or TBM “caseness” 
could provide further insight into the misclassifica-
tion of cases as a result of poor diagnostic strategies for 
TBM. Second, including the information from prob-
able and possible TBM cases in model development 
would result in a more applicable model for probable 
and possible cases, with the intention that the model 
could better predict TBM for these persons.
•  Conduct a misclassification bias analysis. This step 
is important since there is no “gold-standard” diag-
nostic criteria for TBM diagnosis so there is likely 
misclassification bias. Many of the diagnostic meth-
ods used to ascertain TBM, such as TB culture in CSF, 
have known sensitivities and specificities that will be 
used towards reclassifying cases. Model(s) will be 
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developed with the reclassified case statuses and 
compared to the model(s) developed with the original 
case classification.
We will also assess risk of bias for each included study using 
the QUADAS-2 tool11. This tool comprises four domains: par-
ticipant selection, predictor measurement, and outcome definition 
and measurement. Each domain is assessed in terms of risk of 
bias and are also assessed in terms of concerns regarding appli-
cability. Signaling questions are included to help judge risk of 
bias.
Registration
This review is registered with PROSPERO, number 
CRD42018110501.
Presenting and reporting of results
We will report the results according to the Preferred Reporting 
Items for a Systematic Review and Meta-analysis of Individual 
Participant Data Statement (PRISMA-IPD)10. This will include 
a flow diagram to summarise the study selection process 
and detail the reasons for exclusion of studies screened as 
full text. We will publish our search strategy and quality-scoring 
tool as supplementary documents. Quantitative data will be 
presented in evidence tables of individual studies as well as in 
summary tables. We plan to report on quality scores and risk of 
bias for each eligible study. This may be tabulated and accom-
panied by narrative summaries. A descriptive analysis of the 
strength of evidence assessment will be reported. The final 
prediction model(s), that is, the variable-selected model(s) with 
the highest area under the receiver operating characteristic 
curve (AUC), will be implemented in a Smart phone application 
and a Web-based calculator and graphically depicted using 
nomograms.
Discussion
TBM is a serious public health concern with delayed diagnosis 
and treatment being important risk factors for poor outcome1. 
At least 10 attempts have been made to develop clinical predic-
tion models to aid the rapid diagnosis of TBM but none have 
been broadly successful. The aim of this project is to combine 
data from multiple sources to develop and internally validate 
a novel clinical prediction model, which will be made easily 
available as a smart phone application and a Web-based calculator. 
By combining data from multiple geographical locations and 
using advanced machine learning techniques it is hoped that 
we can develop a model that is broadly generalizable around 
the world. Further work will involve external validation of the 
model(s) and testing in randomised controlled trials.
Ethics
No specific ethical approval has been sought for this system-
atic review. Authors who submit IPD will be asked to confirm 
that the dissemination of anonymised data was included in the 
original patient consent document.
Data availability
Underlying data
No data is associated with this article.
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Kym I.E. Snell   
Centre for Prognosis Research, School of Medicine, Keele University, Keele, UK 
The authors have addressed some of my previous comments. However, there are several points 
that I have to still query. 
 
Firstly, I think there has been some confusion in the use of the terms ‘case-mix variation’ and 
heterogeneity. As the project includes an IPD-MA, I was referring to differences in case-mix across 
studies and heterogeneity in performance across studies in line with text in the introduction. 
Therefore, some of the changes to the protocol are rather confusing. 
 
If the authors intend to look at heterogeneity in predictor effects, their approach (a stratified 
intercept model with fixed effect for the predictor effect) will not allow them to investigate this as 
the predictor effect is fixed. If heterogeneity in predictor effects is of interest, then I would 
suggest placing a random effect on the predictor effect allowing the slope to change by study and 
reporting estimates of heterogeneity. If this is not of interest, then please remove mention of 
investigating heterogeneity in predictor effects. 
 
It is not clear what is meant by ‘We will also use this method to assess predictor heterogeneity by 
HIV status, WHO region, and TB burden within each country’? Do you mean evaluate predictors 
within subgroups of these factors, fit interactions between predictors and these effects, or 
something else? 
 
I’m also rather confused by the suggestion of classification and regression trees, supervised and 
unsupervised ML, LCA in relation to case-mix variation. These are just different statistical 
techniques that can be used to investigate clustering of individuals (by characteristics) and doesn’t 
explicitly say how different studies will be used or what the objective is. 
 
The methods for model development and validation are still vague and suggest to me that the 
data from multiple studies will be combined and treated as a single dataset rather than as an IPD-
MA (accounting for clustering by study). IPD-MA can be very challenging, however there is a lot of 
guidance on how to conduct them, particularly by T. Debray and R. Riley. Sadly, much of the 
guidance has either not been considered or been ignored. If using regression modelling, 
clustering by study could be accounted for by using a random intercept or stratified intercept. It is 
then also important to decide how the model would be implemented i.e. what intercept would be 
used for validation in a new study or for new patients in practice (Debray et al., 20131)? I am not 
aware of how clustering can be accounted for when using methods such as CART. 
 
I have some concern about the decision not to impute for missing data, especially given the list of 
28 predictors of interest and no minimum sample size that they aim to achieve. In my experience, 
expecting to receive datasets with 28 predictors of interest is incredibly optimistic. It is more likely 
that both systematically missing data and partially missing data will be a challenge. If every 
dataset was missing just one of those variables, there would be no data left to use. It often ends 
up being a compromise between the number of predictors (and which ones are) considered and 
the number of datasets included. If then also not imputing for partially missing data, further data 
is lost and predictor effects may be biased (e.g. only severe cases get certain tests). This could 
affect your target population and result in models that are not applicable to the population of 
interest. 
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Regarding the decision to develop the model in only confirmed TBM and non-TBM patients, I 
would think that the target population would include probable and possible TBM and therefore 
there would be an applicability issue if the model was developed using an unrepresentative 
subgroup of patients (Moons et al., 20192). These probable and possible cases are also often the 
individuals in which a prediction model has the most potential to be useful. Other options to 
consider are to include them with one or the other of confirmed TBM and non-TBM so as not to 
exclude them. Sensitivity may be to change which outcome they’re grouped with. 
 
Finally the description of bootstrap validation is not correct. Optimism is not a statistic as such but 
can be estimated for each performance statistic of interest. The 'optimism-corrected' statistics are 
then calculated as apparent minus optimism. The optimism for a particular statistic is calculated 
by repeating the model development in each bootstrap sample, calculating the performance in 
the bootstrap sample (where it will be optimistic) and also applying that model back to the original 
dataset (acting as a validation dataset). Repeat lots of times and the average of the differences 
between these is the estimate of optimism. Estimating optimism by bootstrapping is sufficient, no 
need to calculate for other validation approaches like IECV. 
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Centre for Prognosis Research, School of Medicine, Keele University, Keele, UK 
This is a clear and well-written protocol for a systematic review, collection of IPD and IPD meta-
analysis for a new diagnosis model for TBM. I think the aim of the study and details relating to the 
systematic review part are clear, however I have a few comments/questions for clarity and 
reproducibility, mostly regarding what happens once IPD has been collected.
In the introduction the authors mention that case-mix can affect the predictive performance 
of a model and that big datasets can be used to examine the heterogeneity and improve 
the predictive performance. However, I don’t think they really address this issue in the 
methods or say how they will use the IPD to try improve the performance. Heterogeneity in 
performance if the predictor effects are consistent suggests differences in case-mix that are 
not being captured by the predictors in the model. Unless additional variables that are 
thought to improve the model are included, how will this be addressed? Will the authors 
consider recalibrating the baseline risk to different populations for example? 
 
1. 
For the risk of bias assessment, I suggest using items from PROBAST too (excluding the 
analysis domain) which has recently been published and relates to prediction modelling 
studies (Wolff et al., 20191). 
 
2. 
Have the authors considered how much data they would need to acquire to develop new 
prediction models for TBM e.g. any sample size calculations based on likely event rate and 




In my experience, one of the biggest difficulties with IPD-MA like these is how different 
studies record different combinations of variables. Therefore, combining studies for model 
development can be very difficult and it may be necessary to prioritise certain variables (or 
combinations of variables) and use a subset of studies with those variables, hence my 
previous comment regarding sample size. Have the authors considered which variables are 
of particular interest and what they will do if these are not recorded in individual studies? 
How will IPD be selected for developing new models as it is unlikely to all be used? 
 
4. 
How will missing data be handled? If imputing, will this be done within or across datasets? 
 
5. 
It’s not clear if one model will be developed or multiple models (using each of the different 
modelling approaches). If aiming for a single model, how will it be selected? 
 
6. 
Bottom of page 5: I’m not sure what is meant by “Model development will initially be carried 
out using participants with either definite TBM or definitely not TBM. The model will then be 
applied to participants with possible TBM.” Can the authors please clarify? Do they mean 
that possible TBM will be included in the definition of TBM? 
 
7. 
I’m also not sure what is meant by “the training set will be calibrated to optimise the model 
coefficients for best predictive accuracy using AUC-ROC score” (Data synthesis, part 2)? By 
definition, the model will be calibrated to the development data and is therefore optimised 
to the data, which can lead to overfitting. 
 
8. 
Will clustering by dataset be accounted for in the model development e.g. using a random 9. 
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intercept? 
 
Will calibration of the model be assessed? This is also likely to be heterogeneous in different 
populations and therefore may need tailoring to different populations. In contrast, the AUC 
depends on the case-mix and will be lower in more homogeneous populations which 
doesn’t mean the model doesn’t work well. 
 
10. 
I don’t see the point in splitting each dataset for development and validation, especially 
when some studies are likely to be small (min. sample size of 10 so even fewer events). The 
internal-external cross-validation is a better approach as it still retains the external 
validation element and will help evaluate the heterogeneity in performance across datasets. 
 
11. 
Have the authors considered the potential for optimism in model development, particularly 
if they have few events and small sample size overall? Will they consider shrinking the 
coefficients (in a regression modelling approach) to correct for optimism? 
 
12. 
Data synthesis, part 3: What threshold will be selected to calculate measures of diagnostic 
test accuracy – will this be based on a predicted probability and pre-specified to avoid bias 
in using ‘optimal’ thresholds? I would also suggest evaluating calibration and discrimination 
as part of the internal validation. 
 
13. 
I would suggest reporting according to the TRIPOD guidelines for the multivariable 
modelling (Collins et al., 20152). 
 
14. 
I would caution against simply developing smart phone apps and web-based calculators 
unless the model demonstrates good predictive ability. Ideally it should be externally 
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We would like to thank Professor Snell for her very helpful comments. 
 
Responses drafted by Anna Stadelman. 
  
READ ME: Comments from Professor Snell are in bold-type font. My responses are below 
each comment. 
                  
This is a clear and well-written protocol for a systematic review, collection of IPD and 
IPD meta-analysis for a new diagnosis model for TBM. I think the aim of the study and 
details relating to the systematic review part are clear, however I have a few 
comments/questions for clarity and reproducibility, mostly regarding what happens 
once IPD has been collected. 
 
1. In the introduction the authors mention that case-mix can affect the predictive 
performance of a model and that big datasets can be used to examine the 
heterogeneity and improve the predictive performance. However, I don’t think they 
really address this issue in the methods or say how they will use the IPD to try [to] 
improve the performance. Heterogeneity in performance if the predictor effects are 
consistent suggests differences in case-mix that are not being captured by the 
predictors in the model. Unless additional variables that are thought to improve the 
model are included, how will this be addressed? Will the authors consider 
recalibrating the baseline risk to different populations for example? 
 
The objective of assessing heterogeneity will be to ascertain case-mix variation among TBM 
cases and non-cases to inform model development. To begin, the contributing datasets will 
be reviewed for sample size, available predictors, and data completeness to inform the 
selection of a modelling approach. A descriptive analysis will be undertaken to understand 
similarities and differences between the contributing datasets. Participant characteristics 
and clinical features will be summarized for each contributing dataset and compared across 
datasets using chi-square, t-tests, or non-parametric methods as warranted. Then, we will 
formally evaluate case-mix variation and predictor heterogeneity via IPD meta-analysis 
using a logistic regression model with stratified intercepts for each study (99). Each TBM 
predictor will be rotated into the model individually to underscore the baseline predictive 
value of each in the different contributing datasets. We will also use this method to assess 
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predictor heterogeneity by HIV status, WHO region, and TB burden within each country. For 
both the informal (descriptive statistics) and formal (IPD meta-analysis) assessment of 
heterogeneity, predictor estimates and their uncertainty intervals will be used to determine 
relative significance as opposed to p-values. Uncertainty intervals for each predictor will 
indicate how reliable the predictor is in terms of its prediction value. Furthermore, looking 
at p-values will only assess statistical significance, which may not be clinically meaningful. 
 
Subsequently, we will employ methods of model development that take into account the 
heterogeneity observed in the IPD meta-analysis. These methods include, but are not 
limited to, classification and regression trees, supervised and unsupervised machine 
learning, Latent component analysis, etc. There may be other sources of heterogeneity that 
become evident during model development which will also be included in the development 
of the clinical prediction rule.   
 
 
2. For the risk of bias assessment, I suggest using items from PROBAST too (excluding 
the analysis domain) which has recently been published and relates to prediction 
modelling studies (Wolff et al., 20191).   
 
Thanks for the recommendation. 
 
 
3. Have the authors considered how much data they would need to acquire to develop 
new prediction models for TBM e.g. any sample size calculations based on likely event 
rate and expected number of candidate predictors for consideration in the models, as 
a target to aim for? 
 
Sample size is difficult to calculate in the context of developing a prediction model. 
However, the size of the development dataset and number of predictors in the final model 
have an impact on the statistical power to detect a difference in TBM case vs. non-TBM case. 
The greater the number of individual participants the more information we have to inform 
the development of the model, specifically the parameterization of the predictors and 
variability explained. More data (i.e. individual participants) better optimizes the individual 
predictors and has a better chance of capturing the variability in TBM case presentations. 
Ultimately, we will make every effort to acquire as many datasets as possible and limit the 
number of predictors to the ones that explain the most variability in TBM diagnosis. 
 
 
4. In my experience, one of the biggest difficulties with IPD-MA like these is how 
different studies record different combinations of variables. Therefore, combining 
studies for model development can be very difficult and it may be necessary to 
prioritise certain variables (or combinations of variables) and use a subset of studies 
with those variables, hence my previous comment regarding sample size. Have the 
authors considered which variables are of particular interest and what they will do if 
these are not recorded in individual studies? How will IPD be selected for developing 
new models as it is unlikely to all be used? 
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We have included in the table which variables are of interest in the development of the 
model(s) (marked with an *). We consider these variables to be the most important for 
model development and inclusion of data into model development will be contingent on the 
representation of these variables in the individual contributing datasets. We will conduct a 
sensitivity analysis with all the individual contributing datasets, regardless of variable 
inclusion, so as to assess any bias introduced into the model by excluding certain datasets.  
 
 
5. How will missing data be handled? If imputing, will this be done within or across 
datasets? 
 
We will not impute any missing data. We will request all the diagnostic data available from 
investigators and any missingness on an individual level may ultimately end up excluding 
that particular individual from model development.    
 
 
6. It’s not clear if one model will be developed or multiple models (using each of the 
different modelling approaches). If aiming for a single model, how will it be selected? 
 
We will create multiple models with the development dataset and compare the fit across 
models via bootstrap, k-fold cross validation, and internal-external cross-validation. 
 
 
7. Bottom of page 5: I’m not sure what is meant by “Model development will initially 
be carried out using participants with either definite TBM or definitely not TBM. The 
model will then be applied to participants with possible TBM.” Can the authors please 
clarify? Do they mean that possible TBM will be included in the definition of TBM? 
 
The model(s) will be developed with confirmed TBM and non-TBM cases, and we will test the 
model(s) on probable and possible TBM cases as part of the sensitivity analysis. 
 
 
8. I’m also not sure what is meant by “the training set will be calibrated to optimise 
the model coefficients for best predictive accuracy using AUC-ROC score” (Data 
synthesis, part 2)? By definition, the model will be calibrated to the development data 
and is therefore optimised to the data, which can lead to overfitting. 
 
Sorry for the confusion. Suggested revision in Version 2.0 of the protocol. 
 
 
9. Will clustering by dataset be accounted for in the model development e.g. using a 
random intercept? 
 
Yes, this will be the aim of the IPD meta-analysis. Each predictor of interest will be rotated 
into a model predicting TBM that has a random intercept for each contributing dataset. The 
aim of this will be to ascertain heterogeneity in predictor strength, which will be accounted 
for in the final model(s). However, the overall aim is to develop a model(s) that accounts for 
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heterogeneity by region, HIV status, and other known causes of heterogeneity in TBM 
cases. Therefore, we are hoping that including these predictors in the final model(s) will 




10. Will calibration of the model be assessed? This is also likely to be heterogeneous in 
different populations and therefore may need tailoring to different populations. In 
contrast, the AUC depends on the case-mix and will be lower in more homogeneous 
populations which doesn’t mean the model doesn’t work well. 
 
Yes, model(s) calibration will be assessed and you bring up important points about the 
metrics for calibration and discrimination.   
 
 
11. I don’t see the point in splitting each dataset for development and validation, 
especially when some studies are likely to be small (min. sample size of 10 so even 
fewer events). The internal-external cross-validation is a better approach as it still 
retains the external validation element and will help evaluate the heterogeneity in 
performance across datasets. 
 
Agreed. We will revise our internal validation approach to include bootstrap, cross-
validation (k-fold), and internal-external validation. Bootstrap validation tells us more about 
the validity of predictor variable selection in algorithm development, which is useful for 
assessing how well our predictors assess TBM diagnosis within different samples. 
Simulations have demonstrated that bootstrap is the best approach to internal validation as 
it appropriately reflects all sources of model uncertainty, especially in predictor variable 
selection (113). We will then utilize a k-fold cross-validation approach to assess the 
validation of the model approach and accuracy of model fit. The resulting c-statistic will 
convey overall model optimism and accuracy of model fit. The predictive model(s) will be 
further validated using ‘internal-external cross-validation’, which is a multiple validation 
approach that accounts for multiple studies by rotating which are used toward model 
development and validation (99). 
 
 
12. Have the authors considered the potential for optimism in model development, 
particularly if they have few events and small sample size overall? Will they consider 
shrinking the coefficients (in a regression modelling approach) to correct for 
optimism? 
 
High optimism, indicative of overfitting, can be corrected via shrinkage and we will consider 
this approach if overfitting is evident. However, we do not anticipate that we will encounter 
overfitting due to the data reduction step described in Version 2.0 of the protocol. 
 
 
13. Data synthesis, part 3: What threshold will be selected to calculate measures of 
diagnostic test accuracy – will this be based on a predicted probability and pre-
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specified to avoid bias in using ‘optimal’ thresholds? I would also suggest evaluating 
calibration and discrimination as part of the internal validation. 
 
We will assess optimism, calibration, and discrimination as part of the internal validation 
approach and have discussed this process further in Version 2.0 of the protocol. As for 
determining a pre-specified predictive threshold for defining TBM versus not, there is little 
information in the literature to inform an appropriate cutoff for TBM. Prior prediction 
models have used ROC curve to determine an optimal cutoff. Furthermore, this is the first 
study to include data from different populations world-wide. As such it is difficult to pre-
specify the optimal predictive cutoff. 
 
 
14. I would suggest reporting according to the TRIPOD guidelines for the multivariable 
modelling (Collins et al., 20152). 
 
Great! Thanks for the recommendation. 
 
 
15. I would caution against simply developing smart phone apps and web-based 
calculators unless the model demonstrates good predictive ability. Ideally it should be 
externally validated first before considering it as a tool for use in practice. 
 
Absolutely agree. Developing an application and/or website calculator is our end goal, but 
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Ravindra Kumar Garg   
Department of Neurology, King George's Medical University, Lucknow, Uttar Pradesh, India 
I read with interest the protocol that aims to identify and validate a set of clinical predictors that 
accurately identify patients with definite tuberculous meningitis and absence of tuberculous 
meningitis. Conventionally, microscopy for acid-fast bacilli, commercial nucleic acid amplification 
test for Mycobacterium tuberculosis or mycobacterial culture of cerebrospinal fluid, are the tests 
that are used to bacteriologically confirm the diagnosis of tuberculous meningitis. 
  
In developing countries and countries with a very high tuberculosis burden, tuberculous 
meningitis is encountered very frequently. Tuberculous meningitis is the commonest CNS 
infection seen in Neurology and Medicine indoors. Facing resource constrains, we always have to 
rely on clinical, imaging and cerebrospinal fluid parameters. Despite constrains, we are able to 
make reliable diagnosis of tuberculous meningitis most of the time. Our classical teaching points, 
to diagnose tuberculous meningitis, are often accurate. With a clinical diagnosis of meningitis 
along with characteristic cerebrospinal fluid findings help in making reasonable and prompt 
diagnosis enabling to start antituberculosis treatment with confidence. Raised cerebrospinal fluid 
lymphocyte count and markedly raised protein are characteristically seen in tuberculous 
meningitis. 
  
Certain clinical signs are very specific to tuberculous meningitis. For example, sixth nerve 
involvement and vision loss in points towards a basal meningeal involvement and tuberculous 
meningitis. Other cranial nerve involvements are very infrequent. In patients with multiple cranial 
nerve palsies, fungal infection and a malignancy are more likely possibilities. As per observation, 
headache and fever are often not dominant features, and they are never presenting features. 
Similarly, neck rigidity may not be present in many patients. In cryptococcal meningitis, severe and 
dominant headache may be a presenting feature. Presence of extrapyramidal movements is a rare 
manifestation of tuberculous meningitis in adults. Extrapyramidal movements are more frequent 
in children. 
  
Computed tomographic findings, if present, are quite characteristic of tuberculous meningitis. 
Basal exudates along with hydrocephalus with or without tuberculoma and periventricular infarcts 
indicates tuberculous meningitis and differential diagnosis option are then limited. A search for 
spinal cord involvement, we believe, if present, add to the diagnostic accuracy.  A combination of 
optochiasmatic arachnoiditis and spinal  lumbo-sacral arachnoiditis, in my opinion, is probably as 
accurate as bacteriological confirmation. Demonstration of paradoxical reaction, if present, also 
helps us in substantiating the reliable diagnosis of tuberculous meningitis. 
  
Tuberculous meningitis, frequently, is a manifestation of more disseminated tuberculosis. Search 
for other sites of involvement often help us establishing clinical diagnosis. For example, ordinary 
X-ray chest shows additional pulmonary involvement. Many cases surprisingly show asymptomatic 
military tuberculosis. Lymph adenopathy and spinal vertebral tuberculosis are also seen in many 
cases. 
  
Diagnostic caution is exercised in elderly patients and HIV infected patients. In these two groups, 
there are high chances of alternative diagnosis. We routinely perform tests with India ink 
preparation and detection of malignant cells. Still, distinctive features of tuberculous meningitis 
help in diagnosis of tuberculous meningitis in these two populations as well. Aspergillosis has a 
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more aggressive course and large vessel involvement is more common. In tuberculous meningitis 
infarcts are usually small and periventricular.  
  
Another issue that need to be addressed is diagnosis of drug-resistant tuberculous meningitis. 
XpertMTB/RIF test, which is now readily available, start discovering drug-resistant tuberculous 
meningitis in increasing number.  This is not surprising because India harbors the major portion 
of global drug-resistant tuberculosis problems. This issue also needs to be given due emphasis. 
  
I greatly appreciate the investigators efforts to evolve a predictive logistic model to accurately 
diagnose definite tuberculous meningitis. There are certain points that I highlighted that need to 
be re-looked and can be incorporated in this protocol. 
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